Osteogenic implants for soft tissue

• US 20070003598A1
• Filed: 09/08/2006
• Published: 01/04/2007
• Est. Priority Date: 08/06/2003
• Status: Abandoned Application

• Current Assignee: Warsaw Orthopedic Incorporated (Medtronic Plc)
• Original Assignee: Warsaw Orthopedic Incorporated (Medtronic Plc)
• Inventors: Trieu, Hai
• Application Number:
  US11/517,694
• Publication Number:
  US 20070003598A1
• Time in Patent Office: Days
• US Class Current: 424/426
• CPC Class Codes: A61F 2002/30586 having two or more inflatable pockets or chambers
• CPC Class Codes: A61F 2002/30677 Means for introducing or releasing pharmaceutical products, e.g. antibiotics, into the body
• CPC Class Codes: A61F 2002/444 for replacing the nucleus pulposus
• CPC Class Codes: A61K 47/32 Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers , poly(meth)acrylates, or polyvinyl pyrrolidone
• CPC Class Codes: A61K 47/34 Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers A61K47/10 takes precedence
• CPC Class Codes: A61K 9/0024 Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue compositions for intravenous administration, normal injectable solutions or dispersions for, e.g. subcutaneous administration A61K9/0019; brain implants A61K9/0085; (coated) prostheses, catheters or stents A61L
• CPC Class Codes: A61L 2300/254 Enzymes, proenzymes
• CPC Class Codes: A61L 2300/414 Growth factors
• CPC Class Codes: A61L 2300/45 Mixtures of two or more drugs, e.g. synergistic mixtures
• CPC Class Codes: A61L 2300/602 Type of release, e.g. controlled, sustained, slow
• CPC Class Codes: A61L 2300/622 Microcapsules
• CPC Class Codes: A61L 2430/38 for reconstruction of the spine, vertebrae or intervertebral discs
• CPC Class Codes: A61L 27/54 Biologically active materials, e.g. therapeutic substances A61L27/227 takes precedence

Abstract

An osteogenic implant includes a degradation agent in solid form and an osteogenerative agent in solid form. The osteogenic implant is configured to release the degradation agent prior to releasing the osteogenerative agent.

Claims

1. An osteogenic implant comprising:

a degradation agent in solid form; and

an osteogenerative agent in solid form;

wherein the osteogenic implant is configured to release the degradation agent prior to releasing the osteogenerative agent.

2. The osteogenic implant of claim 1, wherein the osteogenerative agent is an osteoconductive agent.

3. The osteogenic implant of claim 1, wherein the osteogenerative agent is an osteoinductive agent.

5. The osteogenic implant of claim 1, wherein the degradation agent includes a nucleolytic agent.

8. The osteogenic implant of claim 1, wherein the degradation agent is included in a microsphere.

9. The osteogenic implant of claim 8, wherein the microsphere is included in a solution.

11. The osteogenic implant of claim 1, wherein the degradation agent is included in an outer layer of the osteogenic implant surrounding a core layer including the osteogenerative agent.

12. The osteogenic implant of claim 1, further including an outer layer having an opening, wherein the degradation agent is included in a first region within the outer layer and the osteogenerative agent is included in a second region within the outer layer.

13. The osteogenic implant of claim 12, wherein the first region is closer to the opening than the second region.

14. The osteogenic implant of claim 1, wherein the degradation agent is included in a polymeric matrix.

17. The osteogenic implant of claim 1, wherein the osteogenerative agent is included in a polymer matrix.

20. The osteogenic implant of claim 1, further comprising an anesthetic agent or an analgesic agent.

21. The osteogenic implant of claim 20, wherein the osteogenic implant is configured to release at least a portion of the anesthetic agent or the analgesic agent in conjunction with the degradation agent.

25. The osteogenic implant of claim 1, wherein the osteogenic implant includes an elongated form and a tapered end.

4. (canceled)

6-7. -7. (canceled)

10. (canceled)

15-16. -16. (canceled)

18-19. -19. (canceled)

22-24. -24. (canceled)

26. An osteogenic implant comprising:

a first polymer matrix including a degradation agent; and

a second polymer matrix including an osteogenerative agent;

wherein the first polymer matrix is configured to release at least a portion of the degradation agent prior to time at which the second polymer matrix is configured to release the osteogenerative agent.

27. The osteogenic implant of claim 26, wherein the osteogenerative agent is an osteoconductive agent.

28. The osteogenic implant of claim 26, wherein the osteogenerative agent is an osteoinductive agent.

33. The osteogenic implant of claim 26, wherein the first polymeric matrix includes a hydrogel.

34. The osteogenic implant of claim 26, wherein the first polymeric matrix includes a bioresorbable polymer.

37. The osteogenic implant of claim 26, further comprising an anesthetic agent.

38. The osteogenic implant of claim 37, wherein the osteogenic implant is configured to release at least a portion of the anesthetic agent in conjunction with the degradation agent.

29-32. -32. (canceled)

35-36. -36. (canceled)

39-40. -40. (canceled)

41. A medical kit comprising:

an osteogenic implant including;

a degradation agent in solid form; and

an osteogenerative agent in solid form;

wherein the osteogenic implant is configured to release the degradation agent prior to releasing the osteogenerative agent; and

a tool configured to locate the osteogenic implant proximate to a vertebral structure.

42. The medical kit of claim 41, wherein the tool includes a lumen and wherein the osteogenic implant is configured to fit within the lumen.

43-68. -68. (canceled)